Blood cancers

Life After Stopping TKIs study shows discontinuation feasible in select CML patients

Discontinuation of tyrosine kinase inhibitors (TKIs) is feasible in patients with chronic myeloid leukaemia (CML) who have sustained a deep molecular response and is associated with significant improvements in patient reported outcomes, data from the LAST (Life After Stopping TKIs) trial shows. The US study included 172 patients with chronic-phase CML who had a minimum ...

Already a member?

Login to keep reading.

© 2021 the limbic